NEDA: an emerging concept in MS

 

REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – The assessment of treatment response has evolved over the past two decades of DMT use, with early trials focusing on relapse rates and disability progression. Indeed, the pivotal trial of glatiramer acetate did not evaluate the effect of treatment on MRI (Johnson et al. Neurology 1995;45:1268-1276).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page